Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies

Lisa G. Shaffer1*, Mindy P. Dabell1, Allan J. Fisher2, Justine Coppinger1, Anne M. Bandholz1, Jay W. Ellison1, J. Britt Ravnan1, Beth S. Torchia1, Blake C. Ballif1 and Jill A. Rosenfeld1

1Signature Genomic Laboratories, PerkinElmer, Inc., Spokane, WA, USA
2Commonwealth Perinatal Services, Richmond, VA, USA
*Correspondence to: Lisa G. Shaffer. E-mail: lisa.shaffer@perkinelmer.com

ABSTRACT

Objective To demonstrate the usefulness of microarray testing in prenatal diagnosis based on our laboratory experience.

Methods Prenatal samples received from 2004 to 2011 for a variety of indications (n = 5003) were tested using comparative genomic hybridization-based microarrays targeted to known chromosomal syndromes with later versions of the microarrays providing backbone coverage of the entire genome.

Results The overall detection rate of clinically significant copy number alterations (CNAs) among unbiased, nondemise cases was 5.3%. Detection rates were 6.5% and 8.2% for cases referred with abnormal ultrasounds and fetal demise, respectively. The overall rate of findings with unclear clinical significance was 4.2% but would reduce to 0.39% if only de novo CNAs were considered. In cases with known chromosomal rearrangements in the fetus or parent, 41.1% showed CNAs related to the rearrangements, whereas 1.3% showed clinically significant CNAs unrelated to the karyotype. Finally, 71% of the clinically significant CNAs found by microarray were below the resolution of conventional karyotyping of fetal chromosomes.

Conclusions Microarray analysis has advantages over conventional cytogenetics, including the ability to more precisely characterize CNAs associated with abnormal karyotypes. Moreover, a significant proportion of cases studied by array will show a clinically significant CNA even with apparently normal karyotypes. © 2012 John Wiley & Sons, Ltd.
increase in detection of clinically relevant alterations in 5% to 8% of cases (depending on the indication for study), the majority of which would not be detected by karyotype analysis.

METHODS

Prenatal samples from amniotic fluid, chorionic villi, fetal blood, or products of conception were received by our laboratory from July 2004 through December 2011 for cytogenetic diagnosis using various microarrays targeted to known chromosomal syndromes with later versions of the microarrays providing backbone coverage of the entire genome (http://www.signaturegenomics.com/detection_rates.html). Although this laboratory participated in the National Institute of Child Health and Human Development-sponsored clinical trial in prenatal microarray testing,17 none of the samples reported here were received as a part of that study. All data used in the analyses presented here were gathered or generated during the process of clinically approved microarray-based comparative genomic hybridization testing for routine patient care. Excluding samples that failed to generate results, a total of 5003 samples were tested for a variety of indications.

Microarray analysis was performed as previously described.4 Results were reported to physicians as normal (no clinically significant CNA, with or without benign CNAs identified), with a variant of uncertain significance (VOUS), or clinically significant (abnormal). A VOUS is defined as an alteration of unclear clinical relevance that has not been previously identified in a laboratory’s patient population, has not been reported in the medical literature, has not been found in publicly available databases, or does not contain any known disease-causing genes.15 All data were retained in our laboratory information management system. Data from all cases resulting in abnormal or VOUS results were also captured in our database (Genoglyphix® Chromosomal Aberration Database, Signature Genomics, Spokane, WA, USA). For this study, our laboratory information management system and the Genoglyphix Chromosomal Aberration Database were searched to identify all prenatal cases. Each case was reviewed (by authors MPD and JAR) and categorized according to the result (i.e. normal, VOUS, or abnormal) and indication for study (IFS). Although cases may have had more than one IFS, cases were counted only once and placed into the category with the most significant risk for a chromosome abnormality. The stratification of categories was a known abnormal karyotype in which the family desired further characterization of the anomaly (n = 648), family history of a parent known to carry a chromosome rearrangement or imbalance (n = 62), fetal demise (n = 417), abnormal ultrasound (n = 2858), abnormal first or second trimester screen (n = 77), other family history of a genetic condition (n = 487), advanced maternal age (AMA) (n = 346), parental anxiety (n = 95), and other/not specified indications (n = 13). Terminated pregnancies were not considered to be fetal demises. Those cases referred for abnormal ultrasound findings were further stratified according to the clinical phenotype, including anomalies in multiple organ systems (n = 808), anomalies in single organ systems (n = 1773), isolated soft marker(s) (n = 77), other nonstructural anomalies (n = 134), and other/not specified (n = 66) (see Shaffer et al., accompanying article).18 Cases with unclear results were further reviewed (by authors LGS and JAR) and in some cases, reassigned to the normal or abnormal groups as appropriate based on new knowledge gained from the medical literature and from our own experience since the initial reporting of the case. A subset of the 5003 cases have been previously published (n = 1878)2,4,15; therefore, some classifications have been updated since previous analyses. Detection rates for abnormal and VOUS results were calculated after removing cases referred with known abnormal karyotypes, family history of a parental rearrangement, and fetal demise because of the increased chance (bias) of detecting clinically significant CNAs in these samples. Abnormal results were further stratified based on the size of the alteration (by author JAR). If the abnormality was an unbalanced translocation, the largest chromosomal segment affected by the translocation determined whether the case was placed in the ≥10 Mb or <10 Mb category.

RESULTS

Cases were received from clinicians and laboratories from the US and abroad. Specimen types tested include cultured amniocytes (n = 3269, 65%), direct amniotic fluid (n = 343, 7%), cultured chorionic villi (n = 854, 17%), direct chorionic villi (n = 63, 1%), fetal blood (n = 25, 0.5%), products of conception (n = 432, 9%), and DNA from unspecified sources (n = 17, 0.3%). For ongoing pregnancies from November 2007 to December 2011, the average (mean) turnaround time between time of specimen receipt and initial reporting of array results was 7.5 days (range: 1–75 days, median 6 days); common reasons for delays included time for culturing, insurance verification, and holding the specimen for other test results. After excluding potentially biased cases, the overall detection rate of clinically significant results was 5.3% (207/3876). The data were further stratified based on the IFS, and these detection rates and rates of VOUS are shown in Table 1. As predicted, fetal demises had a significantly higher detection rate of clinically significant results (8.2%, 34/417) than the rest of the IFS combined (5.3%, 207/3876) (two-tailed p = 0.024, Fisher’s Exact test).

Of the 5003 prenatal specimens, 56.3% (n = 2819) were referred with normal karyotypes, 13% (n = 648) had known abnormal fetal karyotypes at the time of array testing, 16% (n = 802) had karyotyping carried out concurrently with microarray testing, and 14.7% (n = 734) had an unknown status of karyotypes. Excluding the biased family history and fetal demise categories, the detection rate of clinically significant CNAs was 5.5% (140/2533) among cases with known normal karyotypes, demonstrating that, in general, these detection rates from the whole cohort in this study represent the identification of clinically significant CNAs beyond those detected by karyotype analysis. Table 2 shows the stratification of the clinically significant results, from Table 1, into the <10 Mb and ≥10 Mb categories, representing the reliable resolution for traditional karyotyping. Overall, 71% of the abnormalities identified were <10 Mb and not expected to be identified by conventional cytogenetic analysis. Among these, known microdeletion syndromes were detected in 35 cases (Table 3). In addition, 48% (33/69)
of cases with abnormalities detected by microarray ≥10 Mb were reported with normal conventional karyotypes from the referral laboratories; 6% (4/68) had revised, abnormal karyotypes following the receipt of array results. Figure 1 shows an example of a large, ~19-Mb CNA that was missed by routine cytogenetic testing. In 12 cases, disagreement between mosaic array results and karyotype may have been due to confined placental mosaicism, previously undetected mosaicism, or cultural artifact (especially when the specimen had been in long-term culture before array testing). Three cases were most likely artifact and were not classified as abnormal for this study and are not counted in the 33 cases above, while 9 cases did not have sufficient evidence to rule out cryptic mosaicism (Table 4).

Detection rates for clinically significant abnormalities in cases with a known fetal chromosome abnormality or a family history of a parental rearrangement were calculated separately and are shown in Table 5. Combining all known abnormal karyotypes, 1.4% showed clinically significant CNAs elsewhere in the genome not associated with the known rearrangement.

### DISCUSSION

With the advent of microarray-based comparative genomic hybridization in prenatal diagnosis, a substantially larger proportion of clinically relevant chromosomal abnormalities can be identified, with the exception of some triploidies,19 balanced rearrangements, and cases of uniparental disomy. The resolution of detectable alterations has improved from about 10 Mb or larger-sized rearrangements with karyotyping to a few kb in size with microarray analysis, thus increasing the number of identifiable abnormalities in prenatal diagnosis.

### Detection rates of microarray-based comparative genomic hybridization

Prenatal samples over a period of ~7 years were examined for detection of CNAs by microarray analysis. With the exception of parental anxiety cases (n=95), all indications for study had clinically significant alterations identifiable by microarray. As with other studies that used varying array platforms over time,3,13,14 the cases reported here were also tested with various array platforms and designs.2,4,15 Regardless, the overall detection rate of clinically significant CNAs among unbiased, nondemise prenatal samples for any IFS was 5.3% and was 6.5% when only pregnancies with abnormal ultrasound findings were considered. It is important to note that when we consider only cases tested on oligonucleotide-based arrays,
| Microarray finding | Known microdeletion or microduplication syndrome | Number of deletions | Number of duplications |
|--------------------|-------------------------------------------------|---------------------|------------------------|
| Known microdeletion or microduplication syndrome | | |
| Beckwith–Wiedemann syndrome, 11p15 deletion | 1 | NR |
| 12q14q15 microdeletion syndrome | 1 | NR |
| 1p51 deletion | 1 | NR |
| PWS/AS 1.5q11.1q13 deletion | 2 | Reduced penetrance: 1 |
| Rubenstein–Taybi Syndrome (CREBBP 16p13.3 deletion) | 1 | NR |
| Alveolar Capillary Dysplasia with Mismatch of Pulmonary Veins (FOXF1 16q24.1 deletion) | 1 | NR |
| HNPP (17p12) | 5 | 0 |
| 17q23.2 microdeletion | 1 | 0 |
| 22q11.21 deletion syndrome | | Reduced penetrance: 5 |
| 15q11.2 BP1-BP2 microdeletion | 19 | Benign |
| Microdeletions and microduplications with reduced penetrance | | |
| 15q11.2 BP1-BP2 microdeletion | 19 | Benign |
| Distal 16p11.2 microdeletion/microduplication | 3 | 3 |
| Proximal 16p11.2 microdeletion/microduplication | 3 | 2 |
| 16p12.1 microdeletion | 3 | Benign |
| 16p13.11 microdeletion | 4 | Unclear: 9 |
| 17q12 microdeletion (RCAD) | 4 | 0 |
| 1q21.1 proximal microdeletion (TAR)/microduplication | 6 | 5 |
| 1q21.1 distal microdeletion/microduplication | 3 | 4 |
| 22q11.21 atypical microdeletion | 1 | Unclear: 3 |
| 22q11 distal microdeletion | 1 | 0 |
| NRXN1 deletion | 2 | NR |
| Terminal chromosome abnormalities | | |
| 1p | 1 | 1 |
| 1q | | 1 |
| 4p | 5 | 0 |
| 4q | 1 | 4 |
| 5p | 1 | 0 |
| 5q | 1 | 1 |
| 6p | 3 | 0 |
| 6q | 1 | 2 |
| 7p | 0 | 4 |
| 7q | 6 | 1 |
| 8p | 1 | 2 |
the overall detection rate increases to 6.5% (182/2818), and in
the subset with abnormal ultrasound
findings it increases to
7.6% (165/2161). For all of our unbiased, nondemise prenatal
samples, positive detection rates among the IFS categories
ranged from 0.3% for AMA to 8.2% for fetal demise (Table 1).

Table 3 Continued

| Microarray finding | Number of deletions | Number of duplications |
|--------------------|---------------------|------------------------|
| 8q                 | 0                   | 1b                     |
| 9p                 | 1a                  | 0                      |
| 9q                 | 1b                  | 0                      |
| 10p                | 0                   | 1b                     |
| 10q                | 1b                  | 1b                     |
| 11p                | 0                   | 1b                     |
| 13q                | 2b                  | 0                      |
| 14q                | 1                   | 1b                     |
| 16p                | 1b                  | 1b                     |
| 17p                | 3b                  | 0                      |
| 17q                | 0                   | 2a,b                   |
| 18p                | 0                   | 0                      |
| 19q                | 1b                  | 2a                     |
| 19q                | 0                   | 1b                     |
| 20p                | 0                   | 1b                     |
| 20q                | 0                   | 1b                     |

BP, break point; HNPP, hereditary neuropathy with liability to pressure palsies; NR, nonreciprocal; deletions or duplications are not mediated by nonallelic homologous
recombination, so recurrent reciprocal rearrangements are not reported here; PW/AS, Prader-Willi/Angelman syndrome; RCAD, renal cysts and diabetes; TAR, thrombocytopenia/absent radius; WBS, Williams–Beuren syndrome.

aIncludes case(s) classified as complex; additional abnormalities were present.
bIncludes case(s) with unbalanced translocations.

Figure 1 An 18.9-Mb 2q24q31 deletion identified by microarray in a specimen with a 46, XY karyotype. Microarray plots show a single-copy loss of 806 oligonucleotide probes from the long arm of chromosome 2, identified in cultured amniocytes from a fetus referred with a diaphragmatic hernia, Dandy Walker malformation, ventricular septal defect, and lower limb abnormalities. The deletion includes several disease-associated genes (green boxes), including epilepsy-associated SCN1A and SCN2A and limb abnormality-associated HOXD genes. Probes are ordered on the x-axis according to physical mapping positions (hg18), with the most distal 2p probes to the left and the most distal 2q probes to the right. Values along the y-axis represent log2 ratios of patient:control signal intensities. Results are visualized using Genoglyphix (Signature Genomics).
removed, the rate of detecting significant abnormalities was dependent on the various broad IFS categories ($\chi^2 = 38.03$, $df = 6$, $p < 0.0001$). Thus, while significant CNAs can be found among most categories of IFS, they are more likely to be found in certain categories, demonstrating an increased diagnostic utility of microarray testing among certain subsets of prenatal patients.

Large prospective studies using microarrays for prenatal testing are necessary to assess the detection rates of chromosome abnormalities beyond those detected by karyotyping. In addition to the multicenter National Institute of Child Health and Human Development-sponsored clinical trial, five recent prospective prenatal studies have been published using relatively high-resolution arrays. Three of these studies used bacterial artificial chromosome-based arrays while two used bacterial artificial chromosome arrays and oligonucleotide arrays in later years. Combined, these studies tested over 10,000 pregnancies with microarrays and found detection rates over all IFS of ~1% to ~6%. Two studies found 9% to 11% clinically significant abnormal array results in cases with abnormal ultrasound findings. The results from these studies are comparable to our results of clinically significant CNAs in 5.3% for any IFS and 6.5% for pregnancies with abnormal ultrasound findings. In addition, we report an 8.2% detection rate in those cases referred for fetal demise or stillbirth. Specifically in these fetal demise or stillbirth cases, microarray analysis should be considered a superior alternative to karyotyping because DNA can be extracted directly from these hard-to-grow specimens without the need for culturing.

For cases with AMA as the only IFS, previous studies varied in their detection of CNAs that were not identified by karyotype. Fiorentino et al. found one de novo 15q13.1q33 deletion (1/444, 0.2%); Armengol et al. found two de novo microduplications (2/56, 3.6%); Breman et al. found five abnormalities, three of which were undetectable by karyotype, including a deletion of 16p13.11 and two microduplications (3/394, 0.76%); and Lee et al. found 30 abnormalities, ten of which were undetectable by karyotype, including duplication of 22q11.21, Williams–Beuren syndrome, 17p13.1 microdeletion or microduplication. Combining our data with that of these four other studies, 0.5% of AMA (17/3151) had abnormalities detected by array that would not be detectable by karyotyping. Furthermore, assuming 200,000 invasive prenatal tests are performed

### Table 4. Mosaic abnormalities ≥10 Mb seen by microarray but not by karyotype

| Sample type | Karyotype | Interpretation | FISH analysis |
|-------------|-----------|----------------|---------------|
| 40x (cultured villi) | Trisomy 7 | Trisomy 7 in 7/30 (23%) | Cultured villi | CPM or FM |
| 40x (cultured amniocytes) | Trisomy 16 | Trisomy 16 in 2/150 (1%) | Cultured amniocytes | Artifact or FM |
| 40x (cultured amniocytes) | Monosomy X | Monosomy X in 15/17 (88%) | Cultured amniocytes | Artifact or FMMosaic |
| 40x (cultured villi) | Del(16) | Del(16) in 13/55 (24%) | Cultured villi | Artifact or CPM |
| 40x (cultured amniocytes) | Trisomy 8 & 20 | Trisomy 8 in 13/30 (43%); trisomy 20 in 10/30 (33%) | Cultured villi | Likely artifact |
| 40x (cultured villi) | Del(16) | Del(16) in 13/55 (24%) | Cultured villi | Artifact, CPM, or FM |
| 40x (cultured amniocytes) | Del(16) | Del(16) in 13/55 (24%) | Cultured amniocytes | Likely artifact |
| 40x (cultured villi) | Del(16) | Del(16) in 13/55 (24%) | Cultured villi | Likely artifact |
| 40x (cultured amniocytes) | Del(16) | Del(16) in 13/55 (24%) | Cultured amniocytes | Likely artifact |

**FISH**, **fl** in situ hybridization; CPM, confirmed placental mosaicism; FM, fetal mosaicism; POC, products of conception.

**Interpretations are the final interpretation based on all results from follow-up testing (when available), phenotypic information, and time in culture.**
Ability of microarray to detect abnormalities missed by traditional cytogenetic analysis

Of the clinically significant CNAs identified in this study, 71% were less than 10 Mb in size. Among these were 35 deletions of well-documented microdeletion syndromes such as DiGeorge and Prader-Willi/Angelman syndromes; 46 microdeletions associated with reduced penetrance; 3 cases of well-described microduplication syndromes; 16 microduplications associated with reduced penetrance; 8 terminal deletions, including monosomy 1p36 and deletion 7q; 7 cryptic, unbalanced translocations; and 12 complex rearrangements involving two or more chromosomal segments, not presenting as an unbalanced translocation after fluorescence in situ hybridization visualization (Tables 2 and 3). Because many of these abnormalities are below the resolution of karyotyping, they are unlikely to be detected by routine analysis of fetal chromosomes. Because clinically significant alterations were as small as 7 kb (Figure 2), these data also support that laboratories should not use an arbitrary reporting cut-off based on size as previously proposed because significant small aberrations will be missed. Alterations should be examined for genetic content and reported based on those findings.

Interpretation of copy number alterations

The laboratory must interpret results into one of a minimum of four categories: normal (no alterations), normal with benign CNAs (VOUS), or abnormal (clinically significant). In this study, cases with results reported as having unclear clinical significance were re-reviewed and in some cases reassigned as benign variants (about three-fourths of the reclassifications) or clinically significant CNAs (about one-fourth of the reclassifications). The majority of the cases reclassified as significant were microdeletions and microduplications of regions that are now well recognized as syndromes with a wide range of features because of variable penetrance and expressivity. These include deletions of distal 16p11.2, 15q11.2, and 16p12.1; atypical deletions in 22q11.21; and duplications of distal 16p11.2 and proximal and distal 1q21.1. Interestingly, many of these alterations were identified in a parent (21/34 with known inheritance).

With the increased ability to detect CNAs with microarrays, VOUS will be identified. In this study, 4.2% of nondemise cases remained unclear. Some laboratories discriminate between those VOUS that are inherited from a parent and those that are de novo in origin, placing more potential clinical relevance on those that are de novo, while grouping the majority of those inherited as benign, thus effectively lowering the rates of reported VOUS. Our laboratory has typically reported higher

---

**Table 5** Detection rates for cases with a known fetal chromosome abnormality in an on-going pregnancy or fetal demise, or a family history of a parental rearrangement

| Karyotypic abnormality | Imbalance related to the known karyotype (%) | No imbalance (%) | Other unrelated finding, significant (%) | Other unrelated finding, unclear (%) | Total |
|------------------------|---------------------------------------------|------------------|----------------------------------------|------------------------------------|-------|
| Nonmosaic, apparently balanced rearrangement | 19 (7.9) | 207 (86.6) | 4 (1.7) | 9 (3.8) | 239 |
| Balanced translocation | 1.5 (7.9) | 166 (87.8) | 4 (2.1) | 4 (2.1) | 189 |
| Inversion | 2 (4.5) | 37 (84.1) | 0 (0.0) | 5 (11.4) | 44 |
| Insertion | 2 (33.3) | 4 (66.7) | 0 (0.0) | 0 (0.0) | 6 |
| Mosaic, apparently balanced rearrangement | 0 (0.0) | 5 (100.0) | 0 (0.0) | 0 (0.0) | 5 |
| Nonmosaic, apparently unbalanced rearrangement | 183 (67.5) | 82 (30.3) | 3 (1.1) | 3 (1.1) | 271 |
| Marker or ring chromosome | 47 (53.4) | 38 (43.2) | 1 (1.1) | 2 (2.3) | 88 |
| Suspected deletion | 59 (84.3) | 10 (14.3) | 0 (0.0) | 1 (1.4) | 70 |
| Suspected duplication | 34 (57.6) | 25 (42.4) | 0 (0.0) | 0 (0.0) | 59 |
| Complex rearrangements | 15 (68.2) | 5 (22.7) | 2 (9.1) | 0 (0.0) | 22 |
| Aneuploidy | 16 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 16 |
| Unbalanced translocation | 12 (75.0) | 4 (25.0) | 0 (0.0) | 0 (0.0) | 16 |
| Mosaic, apparently unbalanced rearrangement | 44 (40.0) | 62 (56.4) | 2 (1.8) | 2 (1.8) | 110 |
| Marker or ring chromosome | 41 (44.5) | 47 (51.1) | 2 (2.2) | 2 (2.2) | 92 |
| Other mosaic unbalanced karyotype | 3 (16.7) | 15 (83.3) | 0 (0.0) | 0 (0.0) | 18 |
| Variant | 4 (28.6) | 10 (71.4) | 0 (0.0) | 0 (0.0) | 14 |
| Mismatched genotypic and phenotypic sex | 9 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 |
| Total, abnormal karyotype | 259 (40.0) | 366 (56.5) | 9 (1.4) | 14 (2.2) | 648 |
| Family history of a chromosome rearrangement in a parent | 33 (53.2) | 27 (43.5) | 0 (0.0) | 2 (3.2) | 62 |
rates of VOUS because inheritance from a parent often does not help assign the clinical relevance of the alteration because of the possibility of incomplete penetrance or variable expressivity. This is especially true in the laboratory setting in which clinical information on parents is limited. Thus, reporting criteria seem to differ between laboratories regarding VOUS. In our study, 0.39% (n = 15) had apparently de novo VOUS, and 0.75% (n = 29) had VOUS of unknown inheritance. The sum of these (1.1%) is comparable to VOUS rates in other published studies.

Finding a VOUS prenatally can create challenges in counseling expectant parents, and it has been recommended to provide such information in a complete and nondirective manner. Although microarray testing can introduce uncertainty (and associated anxiety) into a pregnancy by the reporting of a VOUS, this risk should be considered in comparison to the likelihood of identifying clinically significant findings when deciding whether to perform the testing; for example, 6.6% of structural ultrasound abnormality cases and 2.6% of cases with soft marker findings had abnormal results. Additionally, even in those cases in which a VOUS is identified, this result has excluded the presence of a few hundred chromosomal alterations that lead to well-characterized syndromes in the fetus.

For the most part, the detection rates in this study are in addition to the chromosome abnormalities found in routine cytogenetic testing because the cases reported here had normal karyotypes or chromosome analysis was in progress at the time of the microarray testing. Given this added ability to detect significant chromosome alterations in fetuses with abnormalities, this fully justifies the use of microarray testing in trying to identify the etiology of the clinical phenotypes, and thus microarray should be considered as the first test or used concurrently with conventional karyotyping.

Identification of recessive disease risk prenatally
In 2011, our laboratory began reporting fetal cases identified as carriers of recessive disease. In the 1351 nondemise cases tested, 27 (2%) had a heterozygous deletion that included a recessive gene locus. In examining all cases, two had homozygous deletions that are predicted to result in disease, alpha thalassemia in one and Cockayne syndrome in the other.

Figure 2: Homozygous deletions of recessive loci in prenatal specimens. (A) Microarray plot showing a complex pattern of heterozygous and homozygous deletion of 5 oligonucleotide probes from the short arm of chromosome 16 over the alpha thalassemia locus at 16p13.3, identified in cultured amniocytes from a fetus referred with edema. Probes are ordered on the x-axis according to physical mapping positions (hg18), with the most distal 16p13.3 probes to the left and the most proximal 16p13.3 probes to the right. Values along the y-axis represent log2 ratios of patient:control signal intensities. Parental samples were unavailable for array comparative genomic hybridization, but blood work was suggestive of both parents being carriers for alpha thalassemia. (B) Microarray plots from parents and fetus in a prenatal case referred for a family history of intellectual disability. After fetal testing, inspection of this region in the parents showed that the father has a single-copy loss of 3 probes, overlapping ERCC8, a gene associated with Cockayne syndrome, and NDUFAF2, a gene associated with mitochondrial complex I deficiency. The mother has a complex finding of a heterozygous deletion of a single probe within ERCC8 and a more distal heterozygous deletion within NDUFAF2. The fetus inherited both deletions and is therefore predicted to have homozygous loss-of-function of ERCC8 and NDUFAF2. Probes are arranged as in (A), with the most proximal 5q12.1 probes to the left and the most distal 5q12.1 probes to the right. Genes within the region are shown as green boxes. Results are visualized using Genoglyphix (Signature Genomics).
mitochondrial complex I deficiency in the other (Figure 2). Recessive disease may result from homozygous deletion of a recessive disease locus or by heterozygous deletion of one allele and mutation in the other allele. There are now several documented examples of these phenomena, and fetuses with heterozygous deletions identified by microarray analysis could be tested further to exclude a mutation in the intact allele. Correlation of the phenotype, family history, and ethnic background with the particular disease identified can help guide further actions.

Phenotypic implications of copy number alterations

Part of the difficulty in interpreting some clinically significant microarray results is that much of the information available about the clinical consequences of the CNAs may be biased toward increased severity because the CNAs were initially identified in children studied by microarray as a result of some phenotypic abnormality. This biased sampling does not allow for understanding the entire spectrum of the phenotype because clinically normal individuals are rarely investigated by microarrays. In these cases of rare or poorly understood CNAs, case-control studies can be used to understand whether the CNA is likely pathogenic. In addition, although ultrasound can detect fetal anomalies, it cannot detect conditions such as intellectual disability, developmental delay, autism, seizure disorders, and even conditions such as schizophrenia. Microarrays will uncover CNAs that can result in these conditions and identify at-risk fetuses, which is a benefit of the test but also could be a source of parental anxiety. Such issues surrounding phenotypic spectrums and incomplete penetrance should be part of patient pretest counseling for prenatal microarray testing.

The use of microarrays with known abnormal fetal karyotypes

Finally, 634 on-going or terminated pregnancies and 14 cases of fetal demise were referred because of a known chromosome abnormality in the fetus of which the family desired further molecular characterization. In these cases, CNAs associated with the reported chromosomal rearrangement were identified in 40.0%; the array results, therefore, allowed more precise characterization of the size and genomic content of the chromosome anomaly. In contrast, 60.0% of rearrangements showed no gain or loss of the genomic region implicated by conventional chromosome analysis. Thus, in some cases, apparently balanced translocations were balanced (no gain or loss of DNA at the breakpoints based on the resolution of the array used), marker chromosomes did not contain any detectable euchromatin, or other suspected imbalances did not affect euchromatin (Table 5). It is interesting to consider in this context that if microarrays were a first-tier test in prenatal diagnosis, only unbalanced karyotypes would be identified, and those cases that are truly balanced would not be discovered. However, because the discovery of balanced translocations and understanding familial inheritance has implications for future pregnancies and other family members, we should consider the value in performing a concurrent karyotype and contemplate a reduced or limited analysis of the chromosomes to identify balanced rearrangements. Finally, 1.4% of cases showed clinically significant CNAs elsewhere in the genome, unrelated to the apparent chromosomal rearrangement, demonstrating the power of microarray analysis to interrogate the entire genome.

CONCLUSION

Microarray analysis has proven to be an important addition for the examination of the fetal chromosomes. Although the detection rates varied depending on the IFS, overall, 5.3% of nondemise cases demonstrated a clinically significant cytogenetic anomaly after microarray analysis. To the best of our knowledge, by removing cases with known abnormal karyotypes or family history of a known cytogenetic aberration, this detection rate represents an increase in detection of chromosome abnormalities in addition to that uncovered by routine cytogenetic testing. This detection rate is quite significant, especially if applied to the whole population of women undergoing invasive testing each year. Because the goal of invasive testing is to identify chromosome anomalies significant to fetal pathology, microarray testing should be considered a first-tier test for the diagnosis of cytogenetic aberrations in the fetus.

WHAT'S ALREADY KNOWN ABOUT THIS TOPIC?

- Microarray testing has the ability to detect large and small, clinically significant copy number alterations.

WHAT DOES THIS STUDY ADD?

- Through the analysis of a large prospective data set, detection rates of microarray for subsets of the pregnant population can be better understood.
- This study provides strong support that microarray analysis should be seriously considered as a first-tier test in prenatal diagnostics.

REFERENCES

1. Sahoo T, Cheung SW, Ward P, et al. Prenatal diagnosis of chromosomal abnormalities using array-based comparative genomic hybridization. Genet Med 2006;8:719–27.
2. Shaffer LG, Coppinger J, Alliman S, et al. Comparison of microarray-based detection rates for cytogenetic abnormalities in prenatal and neonatal specimens. Prenat Diagn 2008;28:789–95.
3. Van den Veyver IB, Patel A, Shaw CA, et al. Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases. Prenat Diagn 2009;29:29–39.
4. Coppinger J, Alliman S, Lamb AN, et al. Whole-genome microarray analysis in prenatal specimens identifies clinically significant chromosome alterations without increase in results of unclear significance compared to targeted microarray. Prenat Diagn 2009;29:1156–66.
5. Kleeman L, Bianchi DW, Shaffer LG, et al. Use of array comparative genomic hybridization for prenatal diagnosis of fetuses with sonographic anomalies and normal metaphase karyotype. Prenat Diagn 2009;29:1213–7.
6. Tyersman M, Abbott KM, Willatt LR, et al. High resolution array analysis: diagnosing pregnancies with abnormal ultrasound findings. J Med Genet 2009;46:531–41.
7. Faas BH, van der Burgt I, Kooper AJ, et al. Identification of clinically significant, submicroscopic chromosome alterations and UPD in
fetuses with ultrasound anomalies using genome-wide 250 k SNP array analysis. J Med Genet 2010;47:596–94.

8. Maya I, Davidov B, Gershovitz I, et al. Diagnostic utility of array-based comparative genomic hybridization (aCGH) in a prenatal setting. Prenat Diagn 2010;30:131–7.

9. Evangelidou P, Sismani C, Ioannides M, et al. Clinical application of whole-genome array CGH during prenatal diagnosis: Study of 25 selected pregnancies with abnormal ultrasound findings or apparently balanced structural aberrations. Mol Cytogenet 2010;3:24.

10. Park SJ, Jung EH, Ryu RS, et al. Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases. Mol Cytogenet 2011;4:12.

11. Fiorentino F, Caiazzo F, Napolitano S, et al. Introducing array comparative genomic hybridization into routine prenatal diagnosis practice: a prospective study on over 1000 consecutive clinical cases. Prenat Diagn 2011;31:1270–82.

12. D’Amours G, Kibar Z, Mathonnet G, et al. Whole-genome array CGH identifies pathogenic copy number variations in fetuses with major malformations and a normal karyotype. Clin Genet 2012;81:128–41.

13. Breman A, Pursley AN, Hixson P, et al. Prenatal chromosomal microarray analysis in a diagnostic laboratory: experience with >1000 cases and review of the literature. Prenat Diagn 2012;32:351–61.

14. Lee CN, Lin SY, Lin CH, et al. Clinical utility of array comparative genomic hybridisation for prenatal diagnosis: a cohort study of 3171 pregnancies. BJOG: An International Journal of Obstetrics & Gynaecology 2012;119:614–25.

15. Shaffer LG, Dabell MP, Rosenfeld JA, et al. Referral patterns for microarray testing in prenatal diagnosis. Prenat Diagn 2012;32:344–50.

16. Hillman SC, Pretlove S, Coomarasamy A, et al. Additional information from array comparative genomic hybridization technology over conventional karyotyping: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2011;37:6–14.

17. Wapner R. A multicenter, prospective, masked comparison of chromosomal microarray with standard karyotyping for routine and high risk prenatal diagnosis. Am J Obstet Gynecol 2012;206:S2.

18. Shaffer LG, Rosenfeld JA, Dabell MP, et al. Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. Prenat Diagn 2012;32:986–95.

19. Ballif BC, Kashork CD, Saleki R, et al. Detecting sex chromosome anomalies and common triploidies in products of conception by array-based comparative genomic hybridization. Prenat Diagn 2006;26:333–9.

20. Armengol L, Nevado J, Serra-Juhe C, et al. Clinical utility of chromosomal microarray analysis in invasive prenatal diagnosis. Hum Genet 2012;131:513–23.

21. Bachmann-Gagescu R, Mefford HC, Cowan C, et al. Recurrent 200-kb deletions of 16p11.2 that include the SH2B1 gene are associated with developmental delay and obesity. Genet Med 2010;12:641–7.

22. Cooper GM, Coe BP, Girirajan S, et al. A copy number variation morbidity map of developmental delay. Nat Genet 2011;43:38–46.

23. Baldwin EL, Lee JY, Blake DM, et al. Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. Genet Med 2008;10:415–28.

24. McGillivray G, Rosenfeld JA, Gardner RJM, et al. Genetic counselling and ethical issues with chromosome microarray analysis in prenatal testing. Prenat Diagn 2012;32:389–95.

25. Wapner RJ, Driscoll DA, Simpson JL. Integration of microarray technology into prenatal diagnosis: counselling issues generated during the NICHD clinical trial. Prenat Diagn 2012;32:396–400.

26. Coman DJ, Gardner RJ. Deletions that reveal recessive genes. Eur J Hum Genet 2007;15:1103–4.

27. Koifman A, Feigenbaum A, Bi W, et al. A homozygous deletion of 8q24.3 including the NBF1 gene associated with severe developmental delay, dysgenesis of the corpus callosum, and dysmorphic facial features. Am J Med Genet A 2010;152A:1268–72.

28. Girirajan S, Rosenfeld JA, Cooper GM, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet 2010;42:203–9.